Search

Coherus Oncology Inc

Closed

SectorHealthcare

1.14 1.79

Overview

Share price change

24h

Current

Min

1.12

Max

1.1400000000000001

Key metrics

By Trading Economics

Income

-21M

-59M

Sales

2M

14M

P/E

Sector Avg

3.509

55.725

EPS

-0.22

Profit margin

-412.092

Employees

144

EBITDA

3.7M

-30M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+585.84% upside

Dividends

By Acuity

Next Earnings

5 Nov 2026

Market Stats

By TradingEconomics

Market Cap

-10M

212M

Previous open

-0.65

Previous close

1.14

News Sentiment

By Acuity

50%

50%

95 / 339 Healthcare

Coherus Oncology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Sept 2026, 20:07 UTC

Coherus Oncology Inc shares fell sharply, closing at their lowest point of the day, continuing a trend of lower performance over the past four sessions.

24 Sept 2026, 23:50 UTC

Coherus Oncology Inc saw a modest increase in after-market trading, rebounding from four consecutive sessions of declines.

23 Sept 2026, 19:51 UTC

News

Coherus Oncology Inc shares fell sharply as the company appointed Oppenheimer & Co. to advise on the sale of its Legacy BioSim Assets.

22 Sept 2026, 20:01 UTC

Coherus Oncology Inc shares fell sharply, reversing from an early high and currently trading significantly below Monday's close and its 20-day moving average.

21 Sept 2026, 20:01 UTC

Coherus Oncology Inc is trading higher, rebounding from an early low and peaking in the early afternoon, currently above its 20-day moving average.

18 Sept 2026, 20:02 UTC

Coherus Oncology Inc is advancing sharply, achieving its highest cumulative return of the day, despite remaining below its 20-day moving average.

17 Sept 2026, 20:01 UTC

Coherus Oncology Inc is rising, reaching a peak return today, although it remains below its 20-day moving average and near the lower end of its one-month range.

16 Sept 2026, 19:03 UTC

Coherus Oncology Inc shares fell sharply, continuing a notable decline since Tuesday's close and remaining well below their 20-day moving average.

15 Sept 2026, 20:01 UTC

Coherus Oncology Inc shares are trading lower amid negative market sentiment following a significant drop in the NY Empire State Manufacturing Index for September.

14 Sept 2026, 20:08 UTC

Coherus Oncology Inc shares are higher during Monday's session, continuing a significant advance since Friday's close amid broader market trends and inflation concerns.

9 Sept 2026, 20:07 UTC

Coherus Oncology Inc's shares are lower today, continuing a downward trend since Tuesday. The stock reached a session low amid broader market weakness.

2 Sept 2026, 19:46 UTC

Coherus Oncology Inc. shares are higher today, maintaining momentum since Tuesday's close and remaining above the 20-day moving average.

1 Sept 2026, 20:09 UTC

Coherus Oncology Inc is gaining as the Biotechnology sub-sector shows significant upward movement. The stock remains stable, finishing near its one-month range high.

31 Aug 2026, 20:02 UTC

News

Coherus Oncology shares are lower despite announcing participation in upcoming investor conferences and plans to enhance sales of its PD-1 inhibitor, LOQTORZI.

28 Aug 2026, 23:06 UTC

News

Coherus Oncology's $50 million common share offering pressures shares lower in after-market trading, marking a pullback from recent highs.

27 Aug 2026, 19:46 UTC

Coherus Oncology Inc shares are higher today, continuing an upward trend over three consecutive sessions. The stock remains above its 20-day moving average.

26 Aug 2026, 19:35 UTC

Coherus Oncology Inc is trading higher, maintaining upward momentum since Tuesday's close and performing well above its 20-day moving average.

25 Aug 2026, 20:07 UTC

Coherus Oncology Inc. shares are trading roughly flat amid easing Treasury yields, which typically support equities and enhance investor sentiment toward risk assets.

24 Aug 2026, 20:04 UTC

Coherus Oncology Inc shares are lower today, continuing a broader market decline. No specific company news has been identified to explain the movement.

21 Aug 2026, 20:01 UTC

Correlated Moves

Coherus BioSciences Inc. shares are higher today, reflecting positive momentum in the biotechnology sector and broader trends in related equities since Thursday's close.

20 Aug 2026, 23:16 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting modest gains despite broader market pressures and no specific company news identified.

19 Aug 2026, 20:02 UTC

Coherus BioSciences remains roughly flat during Wednesday's session, with no specific news identified. The broader market also showed little change.

18 Aug 2026, 23:26 UTC

Coherus BioSciences Inc is trading higher in after-market hours, despite broader market pressures from rising bond yields and elevated oil prices.

17 Aug 2026, 23:41 UTC

News

Coherus BioSciences announced a special dividend of contingent value rights, boosting shares in after-market trading following the company's strategic asset sale initiative.

14 Aug 2026, 19:31 UTC

Coherus BioSciences Inc shares are higher today, despite no specific news. Broader market sentiment includes concerns over disappointing U.S. retail sales data.

13 Aug 2026, 19:46 UTC

Social Media

Coherus BioSciences Inc shares are lower, extending a four-session decline. Despite social media optimism, the stock remains below its 20-day moving average.

12 Aug 2026, 23:01 UTC

Coherus BioSciences Inc shares are trading higher in after-market hours, despite recent declines and no specific news to explain the movement.

11 Aug 2026, 19:36 UTC

Coherus BioSciences Inc shares are lower amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports. No specific company news identified.

10 Aug 2026, 23:31 UTC

Coherus BioSciences Inc shares are higher in after-market trading, advancing from a low of 0.81% to a high of 3.25% since Monday's close.

8 Aug 2026, 00:01 UTC

Coherus BioSciences Inc shares rose in after-market hours, recovering from earlier volatility and settling higher since Friday's close despite no specific news identified.

Peer Comparison

Price change

Coherus Oncology Inc Forecast

Price Target

By TipRanks

585.84% upside

12 Months Forecast

Average 7.75 USD  585.84%

High 10 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forCoherus Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Sentiment

By Acuity

95 / 339 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.